Oral N-acetylcysteine for Retinitis Pigmentosa (NCT05537220)
NAC Attack, A Phase III, Multicenter, Randomized, Parallel, Double Masked, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral N-Acetylcysteine in Patients With Retinitis Pigmentosa
🩺 Plain-English Summary (8th-Grade Level)
Retinitis pigmentosa (RP) is an inherited retinal degeneration caused by one of several mistakes in the genetic code. Such mistakes are called mutations. The mutations cause degeneration of rod photoreceptors which are responsible for vision in dim illumination resulting in night blindness. After rod photoreceptors are eliminated, gradual degeneration of cone photoreceptors occurs resulting in gradual constriction of side vision that eventually causes tunnel vision. Oxidative stress contributes to cone degeneration. N-acetylcysteine (NAC) reduces oxidative stress and in animal models of RP it slowed cone degeneration. In a phase I clinical trial in patients with RP, NAC taken by month for 6 months caused some small improvements in two different vision tests suggesting that long-term administration of NAC might slow cone degeneration in RP. NAC Attack is a clinical trial being conducted at many institutions in the US, Canada, and Europe designed to determine if taking NAC for several years provides benefit in patients with RP.
Who can join: Review the eligibility criteria below.
Location: University of California - Davis, Department of Ophthalmology & Vision Science — Davis, California
Age range: 18 Years to 65 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (31 Sites)
Showing the first 25 of 31 sites.
- University of California - Davis, Department of Ophthalmology & Vision Science — Davis, California
- University of Southern California, Keck School of Medicine — Los Angeles, California
- University of California - San Francisco, Department of Ophthalmology — San Francisco, California
- Stanford University, Byers Eye Institute — Stanford, California
- Vitreo Retinal Associates — Gainesville, Florida
- University of Florida - Jacksonville, UF Health Jacksonville — Jacksonville, Florida
- University of Miami, Bascom Palmer Eye Institute — Miami, Florida
- Emory University, Emory Eye Center — Atlanta, Georgia
- University Of Illinois At Chicago — Chicago, Illinois
- Northwestern University — Evanston, Illinois
- University of Iowa, Carver College of Medicine — Iowa City, Iowa
- Wilmer Eye Institute- Johns Hopkins University — Baltimore, Maryland
- Harvard University, Mass. Eye and Ear — Boston, Massachusetts
- University of Michigan, Kellogg Eye Center — Ann Arbor, Michigan
- University of Minnesota, Department of Ophthalmology and Visual Neurosciences — Minneapolis, Minnesota
- Mayo Clinic, Department of Ophthalmology — Rochester, Minnesota
- University of Oklahoma, Dean McGee Eye Institute — Oklahoma City, Oklahoma
- Scheie Eye Institute — Philadelphia, Pennsylvania
- Vanderbilt University, Vanderbilt Eye Institute — Nashville, Tennessee
- Retina Foundation of the Southwest — Dallas, Texas
- University of Utah, Moran Eye Center — Salt Lake City, Utah
- University of Washington, Department of Ophthalmology — Seattle, Washington
- University of Wisconsin - Madison, McPherson Eye Research Institute — Madison, Wisconsin
- Medical College of Wisconsin, The Eye Institute — Milwaukee, Wisconsin
- Medical University of Graz, Department of Ophthalmology — Graz, Styria
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Retinitis Pigmentosa
- Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP) — Phoenix, Arizona
- Natural History of PRPF31 Mutation-Associated Retinal Dystrophy — San Francisco, California
- Prospective Natural History Study of Retinitis Pigmentosa — Pittsburgh, Pennsylvania
- Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION) — Beverly Hills, California
- FIGHT-RP 1 Extension Study — Baltimore, Maryland
- Promising ROd-cone DYstrophy Gene therapY — Miami, Florida
Explore by condition: All Retinitis Pigmentosa clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.